380 related articles for article (PubMed ID: 7208341)
1. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F
Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341
[TBL] [Abstract][Full Text] [Related]
2. [Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)].
Micheli H; Pometta D; Gustafson A
Nouv Presse Med; 1980 Dec; 9(49):3759-62. PubMed ID: 7208343
[TBL] [Abstract][Full Text] [Related]
3. [One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)].
Drouin P; Méjean L; Lambert D; Wülfert E; Debry G
Nouv Presse Med; 1980 Dec; 9(49):3753-7. PubMed ID: 7208342
[TBL] [Abstract][Full Text] [Related]
4. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
Canzler H; Bojanovski D
Artery; 1980; 8(2):171-8. PubMed ID: 7458684
[TBL] [Abstract][Full Text] [Related]
5. Studies in asymptomatic primary hyperlipidaemia. IV. ECG at rest and during exercise and its relation to various lipoprotein classes.
Olsson AG; Ekelund LG; Carlson LA
Acta Med Scand; 1975; 198(1-2):55-73. PubMed ID: 170796
[TBL] [Abstract][Full Text] [Related]
6. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.
Nikkilä EA; Ylikahri R; Huttunen JK
Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):58-63. PubMed ID: 190608
[TBL] [Abstract][Full Text] [Related]
7. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
Farnier M; Bonnefous F; Debbas N; Irvine A
Arch Intern Med; 1994 Feb; 154(4):441-9. PubMed ID: 8117177
[TBL] [Abstract][Full Text] [Related]
9. Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Arzneimittelforschung; 1983; 33(8):1185-90. PubMed ID: 6685498
[TBL] [Abstract][Full Text] [Related]
10. [Beclobrate (Turec) in the treatment of primary hyperlipoproteinemia. II. Results of the treatment in relation to the type of hyperlipoproteinemia].
Sznajd J; Idzior-Waluś B; Korzus G; Zabiński J; Hebda A; Markiewicz M
Przegl Lek; 1990; 47(10):711-4. PubMed ID: 2089450
[TBL] [Abstract][Full Text] [Related]
11. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
Franceschini G; Sirtori M; Gianfranceschi G; Frosi T; Montanari G; Sirtori CR
Artery; 1985; 12(6):363-81. PubMed ID: 4051756
[TBL] [Abstract][Full Text] [Related]
12. [The effect of fenofibrate in various types of hyperlipoproteinemias].
Sucić M
Lijec Vjesn; 1989 Mar; 111(3):93-7. PubMed ID: 2747411
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
Sznajderman M
Przegl Lek; 1984; 41(7):493-9. PubMed ID: 6390536
[No Abstract] [Full Text] [Related]
14. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
[TBL] [Abstract][Full Text] [Related]
15. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
[TBL] [Abstract][Full Text] [Related]
16. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
Lopez Rodriguez J; Martorell J
Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
[TBL] [Abstract][Full Text] [Related]
17. Effect of procetofen on apolipoprotein A I and B concentrations in hyperlipoproteinemia.
Viikari J; Solakivi-Jaakkola T; Lehtonen A
Int J Clin Pharmacol Ther Toxicol; 1982 Aug; 20(8):362-5. PubMed ID: 6811447
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of bezafibrate and micronised fenofibrate in patients with type III hyperlipoproteinemia.
Feussner G; Kurth B; Lohrmann J
Eur J Med Res; 1997 Apr; 2(4):165-8. PubMed ID: 9110923
[TBL] [Abstract][Full Text] [Related]
19. [Long-term treatment of hyperlipoproteinaemia, types IIa and IIb, with etiroxate (author's transl)].
Schwartzkopff W; Russ E
Dtsch Med Wochenschr; 1975 Apr; 100(15):815-21. PubMed ID: 164334
[TBL] [Abstract][Full Text] [Related]
20. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
Lehtonen A; Viikari J
Artery; 1982; 10(5):353-67. PubMed ID: 7181678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
